Tech Transfer Roundup: Inside Merck’s Approach To Academic Partnering
Executive Summary
With later-stage in-licensing assets becoming harder to find, Merck is seeking to work more often and in varied ways with academic and institutional researchers to advance its pipeline. Recent tech transfer deals include Cancer Research UK’s transactions with ProNAi and Artios.
You may also be interested in...
Deal Watch: Genentech Out-Licenses PI3K Inhibitor To Novogen
The Australian firm also buys out Glioblast to add to its capabilities in brain cancer. Meanwhile, India’s Sun Pharmaceutical acquires Auven’s Ocular Technologies, and GlaxoSmithKline partners with Fimbrion in urinary tract infections and with Zai Lab in autoimmune disorders.
Otsuka/Lundbeck Closer To Adding Alzheimer’s Agitation To Rexulti Label
With no currently approved treatment for agitation in Alzheimer’s disease, analysts see a solid revenue opportunity for Rexulti. The companies plan to file a supplemental NDA later this year.
NewAmsterdam Is Behind Another Try At CETP Inhibition, With Menarini’s Help
Years after failures by Merck, Lilly, Pfizer and Roche, NewAmsterdam hopes to bring a CETP inhibitor to market to lower cholesterol, and signs on with Menarini to lead commercial efforts in Europe.